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Introduction
In March 1997, the United States Food and Drug Administration (FDA) approved Nelvinavir (NFV, brand name Viracept) for HIV treatment in humans 1 . NFV is a safe, orally available, and potent drug against HIV-1 and HIV-2 2 . This protease inhibitor (PI) was developed by the private pharmaceutical sector and was a big success in the treatment of AIDS in association with other anti-retroviral drugs 3 . The introduction of PIs combined with HIV reverse transcriptase inhibitors started the era of HAART (highly active anti-retroviral treatment) and is nowadays the standard of care in HIV-AIDS NFV is being progressively displaced from HIV therapeutics by second generation HIV PIs, but has shown interesting off target actions in cancer.
The possible use of anti-HIV drugs against cancer is not new: in the 1990s AZT (zidovudine or azidothymidine) was proposed as antineoplastic drug, but clinical trials did not confirm the preliminary good results obtained in vitro 6 .
That HIV PIs target other molecules besides the HIV protease is quite evident if we examine adverse effects like insulin resistance and lipodystrophy. These and other evidences such as inhibition of tumor cell production of cytokines, anti-angiogenesis, induction of apoptosis and others, suggest off targets effects for PIs, and hints to the concept of a new class of drugs against cancer with multiple anti-cancer effects 6 . NFV, the most important anti-cancer drug of the PI family, if repurposed for cancer treatment, would have an important advantage: it has been used for more than 15 years in HIV treatment and its safety, pharmacokinetics, and adverse events are well known. Serious adverse events are not common with the exception of diarrhea when used at high doses.
Research on NFV as a potentially useful drug for cancer treatment 6 started in 2009.
In this article, we thoroughly review the literature published in this matter and analyze mainly the anti-cancer mechanisms of action of NFV.
Certain controversies regarding NFV activity in lipid metabolism will be considered in depth.
Evidences of nelfinavir anti-cancer activity
A partial response of Kaposi's sarcoma patients to PIs was published in 1998 7 and good results with regression (six complete responses out of 10 patients) 8 . In 1999 Niehues et al. 9 published complete regression of Kaposi's sarcoma in a child treated with highly active anti-retroviral therapy (HAART). Sgadari et al. (2003) described also the inhibition of Kaposi's sarcoma with protease inhibitors and they also mention that these drugs can antagonize vital properties of tumor cells like growth, invasion, tissue remodelling, angiogenesis and survival. They consider these effects to be a consequence of inhibition of invasion, matrix metalloprotease, proteasome and NF-kB signaling 10 . The possible mechanisms of PIs off target activity on tumor cells were described by pioneering work of Schmidtke et al. in 1999 11 : they observed that ritonavir was a modulator of proteasomal activity, allowed normal proliferation when used at low concentrations, but affected protein degradation when present at higher concentrations, and cell cycle was arrested.
Ikezoe et al. 12 described that protease inhibitors increased cellular growth inhibition of all transretinoic acid (ATRA) on cell cultures of myelocitytic leukaemia lines. Protease inhibitors also increased differentiation of acute myeloid leukemia cell lines.
In 2004, Ikezoe 13 described the mechanisms involved in anti-cancer activity of protease inhibitors in myeloma cells.
The mechanisms involved in PIs anti-cancer activity are summarized in chronological order on Table 1 .
Nelfinavir and the ERS-UPR pathway
NFV inhibits the proteases S1P and S2P that are involved in SREBP-1 maturation and other proteases necessary for protein maturation and folding (yet not fully identified) in the endothelial reticulum 49 .
Activation of the unfolded protein response (UPR) starts in the ER when abnormal accumulation of protein is detected
57
. This was investigated thoroughly in yeasts where detection of abnormal protein occurs through Ire1p/Ern1p-mediated signaling from the ER (in mammals there are three sensor proteins IRE1α, PERK and ATF6
58
). UPR activation leads to the specific removal of 252 nucleotides intron from a precursor mRNA of the transcription factor HAC-1p, and the resulting mature mRNA HAC-1p is translated to produce active HAC-1p. This transcription factor translocates to the nucleus and promotes the transcription of chaperones like GRP78 that facilitates removal of abnormal proteins from the ER through retrotranslocation and final disposal by the ubiquitin-proteasome pathway 59 .
HAC1 precursor mRNA is constitutively expressed but not translated until Ire1p/Ern1p sensor removes the necessary nucleotides.
Amendments from Version 1
In this version, a table was included listing past and ongoing clinical trials using nelfinavir in cancer treatment. For activation of SREBP it is necessary that luminal S1P (a protease) cleaves first, followed by intramembrane S2P (another protease) to liberate the transcriptionally active amino-terminal segments of nSREBP. NFV inhibits S1P and S2P, so that transcriptionally active SREBP is not produced. Accumulation of inactive SREBP is one of the UPR initiators. 
See referee reports

REVISED
Interactions of NFV and PIs with other drugs
Indinavir and NFV increase anti-malarial action of artemisinin in vitro on Plasmodium falciparum
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, but artemisinin has also an off target anti-cancer activity. Thus it is reasonable to raise the question: may the association of artesiminin with NFV increase anti-cancer activity?
Another research team 70 has included both, NFV and artesiminin, in a multidrug repurposed protocol (CUSP 9) for the treatment of relapsed glioblastoma.
Celecoxib is an ER stressor that may enhance NFV anti-tumor activity 79 .
Chloroquine and hydroxicloquine are autophagy inhibitors and may work synergistically with NFV, downregulating autophagy and increasing apoptosis 70, 80 .
Nelfinavir may produce overproduction of mcl1 through upregulation of Erk ½, which would reduce apoptosis. The problem can be solved adding sorafenib 81, 82 .
In breast cancer cells, tamoxifen enhances anti-cancer activity of NFV 83 . This synergism was independent of the estrogen receptor status so that the authors consider that the association of NFV and tamoxifen may be advantageous even in patients with no hormone responsive tumors.
Saquinavir has an interesting off target effect: it decreases intracellular ATP in adipocytes 56 . If this effect is similar in tumor cells, an association with metformin and 2-deoxyglucose may produce anticancer activity [84] [85] [86] . There is growing interest on metabolic perturbators in cancer therapy and saquinavir may play a role in this field.
Clinical trials
A phase I dose escalation trial performed in 2014 87 established a MTD (maximum tolerated dose) of 3125 mg twice daily and described that 45% of patients with solid tumors treated with this dose decreased AKT activity and increased ERS indicators. This indicated a possible benefit in neuroendocrine tumor patients and also established that dose limiting toxicity consists in neutropenia.
The dose (3125 mg bid) is more than twice the dose used in HIV treatment. But lower doses, in the range of those used in HIV treatment have been tested, combining nelfinavir with chemoradiotherapy in pancreatic cancer with evidence of efficacy 88 . No control group was used in this research, so comparison was established with known data from previous publications, mainly the favourable possibility of tumor resection after treatment.
Even lower doses (625 mg and 1250 mg bid) were tested in a phase I trial of NSCLC in stages IIIA/IIIB combined with chemoradiotherapy 89 . In nine out of 12 patients a PET scan was available posttreatment with 100% overall response (56% complete response and 44% partial response). Unfortunately, in this trial there was no control group; 50% of the patients (six out of 12) lived for more than 22 months after treatment; 25% (three out of 12) lived without disease for more than 32 months. The results may be considered favourable, even without a control group.
Buijsen et al.
75 recommend a dose of 750 mg NFV bid for a phase II trial of this drug in combination with chemoradiotherapy in locally advanced rectal cancer.
Ongoing phase II trials are mainly in myeloma (associated with bortezomib or lenalomide), glioblastoma patients (associated with chemoradiation), pancreas (associated with gemcitabine and radiation) and lung. (See http://www.clinicaltrials.gov).
The first results of clinical trials did not show a meaningful improvement in the outcome of patients with refractory adenoid cystic carcinoma which is a malignant salivary gland tumor which usually has a poor prognosis. In this case NFV was used as monotherapy 76 .
Why nelfinavir has a role to play in cancer therapy?
Akt activation is an important step in cancer phenotype and is a key player in acquisition and maintenance of cancer hallmarks. Akt is a nodal regulator of cellular survival pathways 90 . There are no drugs at the present time that can inhibit this protein with a good safety profile. Wortmannin, perifosine and other chemicals designed for PI3K/Akt inhibition were too toxic for clinical use or have shown disappointing results, so they did not enter the medical practice. Insulin stimulation of Akt phosphorylation was reduced by 55% at achievable doses 20 . At the same time there is clear evidence that it favours apoptosis and growth inhibition at clinically tolerable and achievable doses.
This anti-Akt activity of NFV can be reinforced by concomitant mTOR inhibition which results in synergistic cytotoxicity 63 . This may be due to the fact that mTOR inhibition without Akt inhibition eliminates a negative biofeedback loop on Akt, producing increased phoshorilation of Akt
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. According to Sarbassov 92 this negative feedback is born in the mTORC2 complex.
According to Carracedo 93 , this negative feedback loop goes as far as PI3K (Figure 6 ). mTOR inhibitors have become a new and important tool against cancer, for example in renal cell carcinoma. But the negative biofeedback loop on Akt must be solved to achieve really good results. NFV could be the clue.
But the most important anti-tumor activity of NVR is not limited to Akt inhibition but ER stress and UPR which may be one of the pathways leading to apoptosis 
Possible controversies
The SREBP pathway for regulation of fat metabolism is initiated through proteolytic cleavage of precursor forms of the SREBPs (125 Kd protein) in ER membranes. When cells are in need of sterol, the precursor SREBPs are hydrolyzed by a 2-step mechanism involving membrane-bound serine protease S1P and a metalloprotease S2P. The N-terminal fragment of SREBP (nSREBP) is a 68 Kd protein that translocates to the nucleus where it works as a promoter-enhancer, binding to sterol regulatory elements located in DNA and activates gene transcription ( Figure 4 ). The nuclear SREBP can be rapidly degraded by a proteasome-mediated mechanism. This provides regulation of gene transcriptional activities 103 .
Transgenic mice over-expressing the constitutively active nuclear forms of the SREBPs (nSREBPs) revealed that overexpression of SREBP-1 or SREBP-2 leads to activation of genes involved in the cholesterol and fatty acid biosynthesis cascades. These transgenic mice displayed the classical features of generalized lipodystrophy, similar to those found in patients under PI therapy 104 .
Riddle et al. in 2001 105 found that PI therapy (they used ritonavir) induced the accumulation of activated SREBP-1 and SREBP-2 in the nucleus of liver and adipose tissues. As a consequence, fatty acid and cholesterol biosynthesis were increased in these tissues. The authors consider that lipodystrophy, hyperlipidemia, and insulin resistance, are the consequence of activated SREBP-1 and SREBP-2 accumulation in the nucleus of liver and adipose tissues. The possible mechanism for these events, according to their criteria is PI suppression of activated SREBP degradation in the nucleus. In summary, Riddles's study showed that ritonavir induced lipid metabolism abnormalities through stabilization of activated SREBP-1 and SREBP-2 in the nucleus of liver and adipose tissues.
These findings are in contrast with those of Guan 49, 106 where NFV inhibited the nuclear translocation of the sterol regulatory element binding protein-1 (SREBP-1) in castration resistant prostate cancer and liposarcoma through inhibition of S1P. This led to accumulation of unprocessed SREBP-1. 3) The target genes for the three SREBP isoforms are different.
NFV------ER stress--------CHOP------up regulation of TRAIL receptor DR5
4) Riddle et al.
found increased SREBP-1 and two in the nucleus of liver and adipose tissues; these SREBPs are the active form (they make no difference between SREBP-1a and SREBP-1c).
5) Guan et al. found increased SREBP in Golgi in the inactive
form (precursor) of tumor tissues treated with NFV.
6) It is possible that tumor tissues that overexpress SREBP-1a behave in a different way than liver and adipose tissue that overexpress SREBP-1c.
7) Riddle et al. tested ritonavir and Guam et al. tested NFV, so the pharmacological effects between these PIs may differ.
A second controversy that stems from the one described above is on the effect of NFV on FAS:
1) According to Guan et al.
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, NFV decreases expression of FAS in liposarcoma cells and castrate resistant prostate cancer as was depicted in Figure 3. 2) According to Lenhard et al. 2000 107 , NFV increases expression of FAS in HepG2 cells (which show many of the normal biochemical functions of non tumor liver parenchymal cells).
May this difference be due to tissue-specific effects of NFV? Does NFV have different effects in tumor tissues and normal tissues?
To definitely solve these controversies, it is necessary to proceed with further experimental research, but the findings described above necessarily raise the doubt that mechanisms that work in tumor cells might be slightly different from those working in hepatocytes and adipocytes.
Possible negative aspects of PIs in cancer
Despite the anti-cancer activity of NFV and PIs, these drugs do not reduce the risk of developing cancer in HIV population 108 and also exert certain depression of immunological functions, interfering with the differentiation program of monocytes into dendritic cells 109 .
PIs increase the expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cell lines increasing the multidrug resistance phenotype 110 .
At the same time ABCB1 expression depends on Akt activation 111 and NFV inhibits partially Akt. The final result of the two antagonistic aspects requires further research.
There are well known undesirable side effects with HIV PIs, like hyperlipidemia, insulin resistance and lypodystrophy (peripheral fat wasting and excessive central fat deposition). One of the main responsible mechanisms of these side effects is the suppression of the breakdown of SREBP in the liver and adipose tissues resulting in increased fatty acid and cholesterol biosynthesis. SREBP accumulation in adipose tissue causes lipodystrophy.
PIs suppress proteasome-mediated breakdown of nascent apolipoprotein (apo) B, resulting in the overproduction of triglyceride. Finally, PIs also suppress the inhibition of the glucose transporter GLUT-4 activity in adipose tissue and muscle. This contributes directly to insulin resistance and diabetes 112 .
Hepatomegaly and hepatic steatosis are direct consequences of the metabolic alterations explained above 105 .
New PIs with anti-cancer activity
In 2010 You et al. 113 synthesized a new indinavir analogue with remarkable anti-cancer activity, similar to NFV: CH05-10. This drug achieved similar cytotoxity to NFV but at lower concentrations, against leukaemia, melanoma, ovarian and prostate cancer cell lines.
In 2009 Saquinavir-NO was introduced 114 ; it showed interesting anti-cancer properties in melanoma xenografts with significantly lower toxicity than saquinavir.
Conclusions
The most relevant mechanisms of PIs anti-cancer activity are Akt inhibition and ER stress.
Following our exhaustive analysis of the current medical literature we conclude that NFV anti-cancer activity is mainly dependent on ER stress-UPR.
Akt inhibition plays also a very important role but is not the unique or main source of anti-cancer effects.
The evidences that support these conclusions are:
1) Even at very high doses of NFV (3,125 mg bid), Akt achieved a level of inhibition around 55% in cell culture 20 .
2) NFV is at the same time a strong ER stressor and an Akt inhibitor.
3) Anti-cancer activity can be achieved at much lower doses than those necessary for Akt inhibition. There is enough evidence of NFV anti-cancer effects and there is adequate knowledge of how this activity works, so that NFV deserves well designed phase II clinical trials, as adjunct cancer therapy.
Associations with proteasomal inhibitors, celecoxib and other cell stressor should also be investigated in the clinical setting due to possible synergy. Tamoxifen with NFV may show interesting results in breast cancer.
Although a large amount of publications, including reviews, have been written on NFV and other PIs in cancer, none has been dedicated to a thorough examination and analysis of the mode of action of these pharmaceuticals as off target drugs (with the exception of the review by Gantt et al.
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). It is hoped that this review will encourage an increment adequately powered and well-designed clinical trials in the various cancer types, beyond the phase I trials that have been recently performed, and specifically trials where these compounds may be tested in association with other known anti-cancer pharmaceuticals like NFV associated to bortezomib and hydroxychloroquine in myeloma, or mTOR inhibitors with NFV in HNSCC and many other possible combinations where the dual feature of NFV, ER stressor and Akt inhibitor, are required.
In myeloma NFV increases proteasome inhibition by bortezomib and may overcome resistance to proteasomal inhibitors. This is an action exclusive of NFV and not shared with other PIs 67 , with the additional advantage that NFV shows the highest cytotoxic activity against primary myeloma cells.
If apoptosis is described as a cascade, then apoptosis stimulator drugs like NFV should be viewed as enhancers of this cascade. An initiator of the cascade is still necessary, for example chemoradiotherapy. After this initial step, apoptosis stimulator drugs increase the amount of cells entering this pathway. This might be one of possible reasons why nelfinavir alone has shown poor results in a clinical trial used as monotherapy.
This does not mean that NFV cannot act as an initiator, but the evidences show that it is prone to be an enhancer of apoptosis rather than an initiator.
Future directions
All the evidences presented in this review reinforce the concept that NFV is a useful drug in cancer treatment. It should be considered in association with chemoradiotherapy in the design of new protocols for diseases like multiple myeloma (in association with bortezomib and hydroxychloroquine) and prostate, pancreas and lung cancer where clinical trials are ongoing. New PIs are being developed with better anti-cancer profile like CH05-10 and saquinavir-NO 77 and further development of new PIs with stronger anti-cancer activity, will probably go on in the future.
Competing interests
No competing interests were disclosed.
Grant information
The author(s) declared that no grants were involved in supporting this work. This is a highly informative and comprehensive review on our current knowledge about the anti-cancer mechanism of nelfinavir. It also deals with the pros and cons of a possible repurposing of nelfinavir (and other HIV PIs) for cancer treatment.
The following amendments and corrections are suggested:
Proteasome: In the abstract, the proteasome is listed among the factors to be "down-regulated" by nelfinavir. Is the proteasome "downregulated" or "inhibited" in its activity? This might be a slight semantic inaccuracy but is important because it reflects different molecular mechanisms. The same applies to Akt, which, according to the author, is mentioned to be "inhibited" in some phrases and to be "downregulated" (as a protein?) by nelfinavir in other phrases.
Independent of this, there is also a controversy in the literature about the ability of nelfinavir to inhibit proteasomal activity. Some authors observed inhibition of proteasomal enzyme activity by HIV PIs, whereas proteasomal target genes such as HIFalpha and cyclins have unexpectedly not been described to accumulate in the presence of PIs. Instead, as mentioned in this review, several of these proteasomal target proteins were found to be downregulated by nelfinavir treatment.
Using yeast terminology (HAC1) to introduce human ER stress mechanisms might confuse the reader. I have problems with the author's proposed classification of PIs into ER stress inducers and Akt inhibitors (Abstract and Conclusion). Ritonavir is listed as an ER stressor only (conclusions "9"), but has been identified by several researchers to cause both ER stress and Akt inhibition. Furthermore, according to our experience, the ability of PIs to reduce Akt activity appears to be dependent on the cell line(s) used. Our group also observed enhanced Akt phosphorylation by nelfinavir in cell lines with low endogenous Akt activity, and Akt activation is also a known response to ER stress.
A combination of nelfinavir with mTOR inhibitors is suggested by the author. There are some independent recent reports indicating that nelfinavir also acts as an mTOR inhibitor.
The ability of nelfinavir to induce oxidative stress should be mentioned, because this may represent one of the reasons why nelfinavir may exert ER stress or other anti-cancer effects. (Fig. 2, for example, suggests undefined "protease inhibition" as the only mechanism of nelfinavir-induced ER stress).
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of the reasons why nelfinavir may exert ER stress or other anti-cancer effects. (Fig. 2, for example, suggests undefined "protease inhibition" as the only mechanism of nelfinavir-induced ER stress).
Some typos in the text and in the figures should be corrected (hidroxychloroquine; phosphorilation; endothelial (=endoplasmic?) reticulum; Bc12 (=bcl2? Fig. 5) ).
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Author Response 03 Jun 2015 , Centro de Diagnostico y Tratamiento OSPIA Zona Norte, Argentina Tomas Koltai Thank you for your deep and knowledgeable revision of this manuscript. I agree with you about the inaccuracies mentioned and there will be corrected in a third version of the article.
Of course, down-regulation and inhibition in the molecular world are two different things, so it is wise to make the modifications you suggested: proteasome is inhibited and not down-regulated by NFV. Akt, being a protein is down-regulated and not inhibited. These will be modified in version 3.
Yeast terminology for proteins playing a role in proteosomal stress may be confusing, so it will be changed for proteins found in mammalian proteosomal stress.
The classification of PIs according their main anticancer activity is based on clinically achievable concentration of the drug. It is quite possible (I found no experimental evidence so far) that at very high concentrations, PIs are both ER stressors and Akt down-regulators. But at doses used in the clinical setting the classification I propose may represent actual differences between the different PIs.
Oxidative stress will be mentioned in version 3. I agree it is an important cause of ER stress.
Amendments will be made to figure 5 along with the remarks you kindly made. The association of NFV and mTOR inhibitors showed interesting results in naturally occurring squamous cell tumors in dogs in our experience (unpublished data). This probably means some sort of synergy between the two. This synergy is mentioned by many authors. NFV acting on mTOR will be particularly highlighted.
Thank you for your interesting revision. All issues you mentioned will be considered in version 3 of this article. 
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